The Academy of Managed Care Pharmacy (AMCP) fully endorses the Code of Ethics for Pharmacists established by the American Pharmacists Association (APhA) as the guiding framework for ethical pharmacy practice.
Today, the Congressional Budget Office (CBO) released an updated cost estimate for the One Big, Beautiful Bill Act (H.R. 1). This cost estimate incorporates the amendments made to H.R. 1 in the hours before the House passed the legislation by a vote of 215-214-1.
Read the Journal of Managed Care + Specialty Pharmacy (JMCP) June 2025 Issue
This week, the House of Representatives passed their budget reconciliation package, the One Big, Beautiful Bill Act (H.R. 1).
On May 22, 2025, the President’s Make America Healthy Again Commission published the MAHA report. The report raises concerns about the chronic childhood disease, processed food, environmental chemicals, lack of physical activity, mental health, and overmedicalization of American children.
Academy of Managed Care Pharmacy (AMCP) issued a statement from CEO Susan A. Cantrell, MHL, RPh, CAE, following passage of the budget reconciliation bill that includes large-scale changes to Medicaid, the Affordable Care Act (ACA), Grad PLUS loans, and other programs.
Under the budget resolution adopted on April 10, 2025, the House Energy & Commerce Committee (E&C) is required to submit changes in laws under its jurisdiction to reduce the deficit by at least $880 billion over the fiscal years (FY) 2025-2034.
On May 12, 2025, President Trump signed an Executive Order (EO) requiring agencies to take steps to encourage manufacturers to provide most-favored-nation pricing for prescription drugs.
PDTs are evidence-based treatments that use software or virtual tools, and sometimes hardware, to deliver a clinical benefit to patients. They have many known uses, helping Americans identify, treat, and manage illnesses across a wide range of conditions, including post-traumatic stress disorder (PTSD), diabetes management, substance and opioid use disorder, attention-deficit hyperactivity disorder (ADHD), chronic back pain, decreasing eyesight, and more. PDTs are subject to review and authorization by the Food & Drug Administration (FDA) and must be prescribed by a health care provider.
AMCP Supports the Medicaid VBPs for Patients Act
